Patents Examined by Karen S Weiler
  • Patent number: 10640542
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 5, 2020
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Jennyfer Bultinck, Sarah Gerlo, Gilles Uze, Franciane Paul, Yann Bordat
  • Patent number: 10577589
    Abstract: Methods of assembling modified adenoviruses, libraries of adenoviral gene modules and compositions thereof are provided herein.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 3, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Colin Powers
  • Patent number: 10545156
    Abstract: The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 28, 2020
    Assignee: RPI Consulting, LLC
    Inventors: Ozlem Equils, Charles F. Simmons
  • Patent number: 10500254
    Abstract: The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 10, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Aaron Deykin
  • Patent number: 10456445
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: October 29, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. Briscoe, Michael Klagsbrun, Sarah Bruneau, Nora Kochupurakkal, Hironao Nakayama
  • Patent number: 10443051
    Abstract: A method for performing homologous recombination between at least a first nucleic acid molecule and a second nucleic acid molecule which share at least one region of sequence homology. A method for improving the efficiency of homologous recombination.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: October 15, 2019
    Assignee: GENE BRIDGES GMBH
    Inventors: Youming Zhang, Jun Fu, Adrian Francis Stewart
  • Patent number: 10350163
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: July 16, 2019
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10273529
    Abstract: Methods and assays are provided for isolating factors including polypeptides, ribonucleic acids (RNAs) and polypeptide complexes that are associated with a target nucleic acid sequence. The target nucleic acid sequence may be comprised within chromatin. The methods are suitable for identification and characterisation of factors including non-coding RNAs (ncRNAs) that associate with specified genomic loci.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: April 30, 2019
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Robert Kingston, Matthew Simon, Jason Allen West
  • Patent number: 10246702
    Abstract: Provided herein are methods and compositions for labeling target nucleic acid molecules with molecular barcodes.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: April 2, 2019
    Assignee: New England Biolabs, Inc.
    Inventors: Cynthia L. Richard, Brendan Galvin
  • Patent number: 10228307
    Abstract: Disclosed herein are matrices for isolating a biological macromolecule from a biological sample, the matrix comprising: a biopolymer capable of binding to the biological macromolecule, wherein the biopolymer is about 0% to about 10% dissolvable in water at a pH of about 6 to about 8 and at ambient temperature but is about 10% to 100% dissolvable in a chaotropic solvent or an organic solvent, and wherein the biopolymer is not squid ring teeth protein; and a surfactant, excipient, or combination thereof. Also provided are methods of using, and kits comprising, the matrices. The disclosed matrices aid in collecting and releasing near quantitative amounts of a biological macromolecule from a biological and/or test sample.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: March 12, 2019
    Assignee: Biofunctions, Inc.
    Inventor: Ali A. Javed
  • Patent number: 10174364
    Abstract: The present invention relates to a method of analyzing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analyzing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 8, 2019
    Assignee: STICHTING VU-VUmc
    Inventors: Thomas Würdinger, Rolf Jonas Nilsson
  • Patent number: 10155944
    Abstract: This invention pertains to improved methods for the synthesis of long, double stranded nucleic acid sequences containing difficult to clone or variable regions.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 18, 2018
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Shawn Allen, Adam Clore
  • Patent number: 10132798
    Abstract: The present invention relates to a microcolumn device for selecting nucleic acid aptamers for single and multiple target molecules, as well as a method for making the microcolumn device. The present invention also relates to a system for selecting nucleic acid aptamers for single and multiple target molecules. The present invention further relates to methods of using the microcolumn device for selecting nucleic acid aptamers for multiple target molecules. Kits that include one or more microcolumn device and/or system of the present invention are also disclosed.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: November 20, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Harold G. Craighead, David R. Latulippe, John T. Lis, Abdullah Ozer, Kylan Szeto
  • Patent number: 10100350
    Abstract: Molecular constructs, populations thereof, arrays, compositions, methods and kits for differentiating a target molecule from an off-target molecule are provided.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: October 16, 2018
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Kenneth J. Breslauer, William H. Braunlin, Leslie C. Beadling, Jens Volker
  • Patent number: 10087485
    Abstract: Compositions and methods are provided for DNA barcoding of designer mononucleosome and polynucleosome (chromatin array) libraries for use, for example, for the profiling of chromatin readers, writers, erasers, and modulators thereof.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: October 2, 2018
    Assignee: The Trustees of Princeton University
    Inventors: Tom W. Muir, Uyen T. T. Nguyen, Manuel M. Mueller
  • Patent number: 10047397
    Abstract: The invention provides methods and reagents for diagnosing breast cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: August 14, 2018
    Assignee: Chronix Biomedical
    Inventors: Ekkehard Schuetz, Julia Beck, Howard Urnovitz
  • Patent number: 10040870
    Abstract: Disclosed is an immune library obtained from a Camelid species containing at antibody chains belonging to at least 7 human germline antibody chains. The presence of a large number of human germline antibody chain families in the library contributes to the usefulness of the library in producing antibodies to human target antigens. The antibodies produced from the library have low inherent immunogenicity.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: August 7, 2018
    Assignee: argenx BVBA
    Inventors: Johannes Joseph Wilhelmus De Haard, Christophe Frederic Jerome Blanchetot, Alex Klarenbeek, Ikbel Achour, Khalil El Mazouari, Jurgen Del Favero
  • Patent number: 10011830
    Abstract: A novel method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the DNA encoding them. Proteins or peptides can be generated by in vitro translation of DNA templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their DNA templates. In particular, high throughput sequencing can be combined with high throughput functional characterization of encoded proteins and peptides, wherein the identity of each protein or peptide is determined by DNA sequencing, and functional studies are carried out directly on each protein or peptide while immobilized on the DNA template encoding it. The methods of the invention should find numerous applications, for example, in high throughput genetic or pharmacological screening, epitope mapping, and protein engineering and directed evolution.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: July 3, 2018
    Assignee: The Board of Trustee of theLeland Stanford junior University
    Inventors: William J. Greenleaf, Curtis J. Layton
  • Patent number: 10011871
    Abstract: The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: July 3, 2018
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Jason H. Bielas
  • Patent number: 10000557
    Abstract: The present invention generally relates to methods of generating antibodies against a species of pathogen that involve identifying the pathogen that is most genetically representative of member of pathogen species and using the identified pathogen to generate an antibody.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: June 19, 2018
    Assignee: DNAE Group Holdings Limited
    Inventors: Colin Dykes, Sergey A. Dryga, Lisa-Jo Ann Clarizia, Eddie W. Adams, Meghan Norvell